

31. Diastereoselective Synthesis of Cyclododeca-1,6-diallenes (= Cyclododeca-1,2,6,7-tetraenes)

by Christoph Boss and Reinhart Keese*


Departement für Chemie und Biochemie der Universität Bern, Freiestrasse 3, CH-3012 Bern

(23.VIII.96)

The synthesis of substituted cyclododeca-1,6-diallenes (= cyclododeca-1,2,6,7-tetraenes) from cyclododeca-5,11-diyne-1,4-diols is described (*Schemes 1 and 3*). The *ca.* 1:1 mixtures of the stereoisomers of the cyclododeca-1,6-diallenes were formed in high yields from the *ca.* 1:1 diastereoisomer mixtures of the 1,4-disubstituted cyclododeca-5,11-diyne-1,4-diols by reactions with Me_2CuLi or *t*-BuMgCl/Cu^I. In mechanistically relevant experiments with the pure diastereoisomers of 1,4-dimethylcyclododeca-5,11-diyne-1,4-diol, it is demonstrated that the configuration is conserved in these reactions. The first synthesis of a 1-substituted cyclododeca-2,8-diyne bearing only one propargylic leaving group gives access to a mixed 12-membered allen-yne (*Scheme 5*).

Introduction. – The intriguing selectivity of allenes in their reactions with electrophiles, radicals, and nucleophiles makes them attractive precursors for C–C bond forming reactions [1]. They are readily available by a variety of methods, many of which make use of $\text{S}_{\text{N}}2'$ -type reactions of propargylic precursors or the MeLi-induced opening of geminal dibromocyclopropanes [2–16]. The chiral nature of disubstituted allenes, predicted by *van't Hoff*, led to the investigation of their configuration which clearly shows that 1,3-disubstituted allenes exist as enantiomers. For cyclic compounds, the minimal ring size, which would allow the strainless incorporation of the linear C=C=C structure and isolation of these allenes was of particular interest: cyclonona-1,2-diene is the smallest stable cyclic allene which has been isolated [1] [17].


For cyclic diallenes, it has been established by *Sondheimer* that the cyclododeca-1,7-diallene (= cyclododeca-1,2,7,8-tetraene) **1** exist in both, the *meso* and the racemic C_2 form [18]. In the cyclodecane series, only the *meso* form of the cyclodeca-1,6-diallene (= cyclodeca-1,2,6,7-tetraene) **2** had been prepared and its structure determined [19].




Recently, we developed efficient synthetic routes to cyclododeca-2,8-diyne with substituents at the propargylic positions of the two alkyne groups [20] and subsequently explored their transformation into cyclic 1,6-diallenes. Due to their ready accessibility

and their stability, the cyclododeca-5,11-diyne-1,4-diols **3a** and **7a** with tertiary- and secondary-alcohol groups, respectively, were chosen as precursors for the synthesis of the cyclododeca-1,6-diallenes **4** and **8**.

Results and Discussion. – When a *ca.* 1:1 mixture of the diastereoisomers of 1,4-dimethylcyclododeca-5,11-diyne-1,4-diyl diacetate (**3b**) was treated with Me_2CuLi , the cyclododeca-1,6-diallene **4** was formed as a *ca.* 1:1 diastereoisomer mixture in 90% yield (*Scheme 1*). The ^{13}C -NMR of **4** showed 16 lines, and the GC analysis revealed two signals in a *ca.* 1:1 ratio which, according to GC/MS, showed both the same fragmentation pattern from m/z 216 for $M^+ 1$).




When the same reaction conditions were applied to the diastereoisomer mixture (*ca.* 1:1) of the acyclic 3,6-dimethylocta-1,7-diyne-3,6-diyl diacetate (**5b**), the diallene **6** was also obtained as a *ca.* 1:1 diastereoisomer mixture in 91% yield (*Scheme 2*). This was apparent from the double set of signals in the ^{13}C -NMR spectrum of **6**. Due to its thermal lability, **6** could not be analyzed by GC [23] [24].



In a further transformation, a *ca.* 1:1 diastereoisomer mixture **7b** reacted with *t*-BuMgCl and CuI to the 1,8-di(*tert*-butyl)cyclododeca-1,6-diallene **8** in 72% yield [8] (*Scheme 3*). The diastereoisomeric *meso*- and *rac*-**8** were formed in a *ca.* 1:1 ratio, which

¹⁾ The reaction of **3b** with H^- as the nucleophile using SmI_2/Pd^0 remained unsuccessful [21] [22].




was confirmed by the double set of signals in the ^{13}C -NMR and the GC analysis with a chiral stationary phase.

In a mechanistically relevant experiment, separate transformations of the pure diastereoisomers of **3b**, obtained by acetylation of the pure diastereoisomers of **3a**, led to products each containing a single diastereoisomer of **4**. The ^{13}C -NMR spectra showed different sets of 8 signals. According to GC analyses on a chiral stationary phase, the precursor *meso*-**3b** was transformed into *meso*-**4**, whereas *rac*-**4** was obtained from the *rac*-precursor²⁾.

These results might be interpreted as follows: the $\text{S}_{\text{N}}2'$ reactions can overall follow a *trans* or a *cis* pathway, with the *trans* pathway usually being favored [7] [10] [12] (*trans* refers to the incoming nucleophile and the leaving group). For a *trans* pathway, it is reasonable to assume that these substitution reactions occur in a plane perpendicular to the idealized plane of the ring system, because only *cis* substitutions could occur in-plane. For the formation of *meso*-**4** by two sequential *trans*- $\text{S}_{\text{N}}2'$ substitutions, the pathway for the second propargylic displacement can be pictured as shown in **9a**. In the case of *rac*-**3b**, the second *trans* substitution reaction with Me_2CuLi may proceed *via* an intermediate with a conformation as depicted in **9b**. Inspection of models indicate that there is severe interaction between the Me group introduced in the first $\text{S}_{\text{N}}2'$ reaction and the CH_2 group in the γ -position. The molecule might, therefore, adopt the less strained conformation **9c** where the CH_2 groups now interfere with the *trans*-mode of Me^- attack in the propargylic position. Alternatively, the stereochemical pathway of the transformation **3b** to **4** could proceed similarly to that proposed for **7b** to **8** (see below). The stereospecific results imply that in *rac*-**3b**, the expected steric interaction is not strong enough to change the mode of the $\text{S}_{\text{N}}2'$ reaction from *trans* to *cis* as described for other examples [7]. These facts only show that the configuration is preserved in the reactions of *meso*- and *rac*-**3b** but do not answer the question of whether the chirality transfer occurs *via* a *cis* or a *trans* mode in these cyclic systems [25]³⁾.


²⁾ The GC of *meso*- and *rac*-**4** contained each an additional peak (t_{R} 20.5 min) of 30–40% intensity, whereas no by-product could be observed in their ^{13}C -NMR spectra. GC/MS Spectra of this peak showed m/z 216 for M^+ , identical to that of **4**. Therefore, the by-product must correspond to an isomer of **4** of unknown structure [23]. This indicates a limited thermal stability of the diastereoisomers of **4**. No additional peaks could be detected in the GC of **8** and **12**, where the allenic unit is substituted by a *t*-Bu group.

³⁾ It is questionable, whether the model calculations which show an angle of 120° for the addition of H^- to $\text{HC}\equiv\text{CH}$ [25] are stereoelectronically relevant for the transformation of propargylic compounds like **3b** with R_2CuLi .



Applying these concepts of steric hindrance to the reaction of **7b** to the diallene **8**, the stereochemical course of the substitution can be rationalized by assuming that a conformational change will occur after the first S_N2' reaction. This would lead to an intermediate with a quasi-equatorial *t*-Bu group and an essentially unhindered alkyne for the second *trans*-substitution proceeding via **10b** to **10c** and to the conformation of *meso*-**8** depicted in Scheme 4. This interpretation is supported by AM1 calculations of a *tert*-butylcyclododeca-1-allen-7-yne, which gave a conformation with a quasi-equatorial *tert*-butyl group. The transformation of *rac*-**7b** to *rac*-**8** can similarly be analyzed according to this scheme.


Scheme 4. Conformational Analysis of the Transformation of *meso*-**7b** to *meso*-**8**



As a first example of the 'missing link' between the dialkynes **3a, b** and **7a, b** and the diallenes **4** and **8**, the cyclic allen-yne compound **12** was prepared from the mono-functionalized dialkyne **11b** [20].

Concluding Remarks. – The transfer of chirality from the propargylic positions in the cyclic alkynes by S_N2' -type reactions to the allenes can be explained in terms of the conformational constraints of the ring system and by steric interactions in the course of the second S_N2' reaction. In the case of **3b**, it has been proven that the diastereoisomers

Scheme 5



are transformed into the diastereoisomers of the tetramethylcyclododeca-1,6-diallene **4** stereospecifically with conservation of the diastereoisomeric relationship.

The ready access of the cyclic 1,6-diallenes **4** and **8** and the cyclic allen-yne **12** calls for a study of their transannular reactions.

We are grateful to the *Stipendienfonds der Basler Chemischen Industrie* for a stipend to C.B. and to the *Swiss National Science Foundation* for generous support of this work (project No. 20.37270.93 and 20-43565.95). The authors would like to thank P. Hübsher and D. Lehmann who have contributed with their excellent experimental skills to the success of these investigations and A. Saxer for thorough GC analyses.

Experimental Part

General. Chemicals were purchased from commercial suppliers and used without further purification. MeLi (*Fluka pract.*) was used as a 1.6M soln. in Et₂O. THF was dried by distillation from Na, Et₂O from NaH. DMAP = 4-(dimethylamino)pyridine. After workup by pouring the mixture onto sat. NH₄Cl soln. and extraction with Et₂O/pentane 1:1, the solns. were dried (MgSO₄). TLC: silica-gel plates *SIL G/UV*₂₅₄ (*Macherey & Nagel*). GC: *Hewlett-Packard-HP-5890* instrument (He, 43 kPa) with a *HP-5-Ultra* capillary column (length 10 m, i. d. 0.2 mm) and a temp. program 40–220° (3°/min); chiral analyses at 20 kPa with a modified cyclodextrin as chiral stationary phase; column *A* (10 m, d.f. 0.25 μm, i. d. 0.3 mm) 100% heptakis{2,3-di-*O*-acetoxy-6-*O*-[(*tert*-butyl)-dimethylsilyl]}-β-cyclodextrin in *OV 1701* and variable temp. programs; *t_R* in min. Prep. HPLC: *715004 ET-250/10-Nuc. 50-7* column (*Macherey-Nagel*); flow 12 ml/min. M.p.: *Büchi-510* melting-point apparatus; uncorrected. IR Spectra: in CHCl₃; *Perkin-Elmer-782-IR* spectrophotometer. NMR Spectra: in CDCl₃ or (D₆) acetone; *Bruker-AC-300* spectrometer (¹H, 300 MHz; ¹³C, 75 MHz); chemical shifts δ in ppm rel. to internal CHCl₃ (δ 7.27) or (D₆)acetone (δ 2.04) for ¹H-NMR and CDCl₃ (δ 77.0) or (D₆)acetone (δ 29.8) for ¹³C-NMR; stack = heavily overlapping signals. MS: *Varian-MAT-CH7A* (70 eV, EI) and *Fisons-Autospec-Q* spectrometer; in *m/z* (rel. %) GC/MS: *VG-Autospec* spectrometer. Reactions were normally performed under Ar or N₂.

1. *Allene Precursors 3b, 5b and 11b.* 1,4-Dimethyl-cyclododeca-5,11-diyne-1,4-diyl Diacetate (**3b**). Under the same conditions as described for **5b** (see below), 0.2 g (0.91 mmol) of 1,4-dimethylcyclododeca-5,11-diyne-1,4-diol (**3a**) [20] gave 0.083 g (30%) of **3b** as a colorless liquid. Better yields were obtained by dissolving **3a** (0.143 g, 0.65 mmol) in Ac₂O (4 ml) followed by slow addition of Et₃N (0.262 g, 2.29 mmol) and DMAP (0.079 g, 0.65 mmol) and stirring at r.t. for 10 h. Workup and chromatography with AcOEt/hexane 2:1 yielded 0.168 g (85%) of **3b** as a colorless liquid. The pure diastereoisomers of **3b** were obtained by separate transformation of the pure diastereoisomers of **3a**, obtained by crystallization [20]. *R_f* (*meso/rac*) 0.60 (AcOEt/hexane 2:1). GC (*meso/rac*): *t_R* 33.98, 34.17 (ca. 1:1). IR (*meso/rac*): 2850s, 2225w, 1710m, 1330s, 1240vs, 1170s, 1100s, 1080vs, 1020s, 930s. ¹H-NMR ((D₆)acetone; *meso/rac*): 1.56–1.78 (2s + stack; 10H); 1.81–1.89 (d, 2H); 2.020 (s, 3H); 2.023 (s, 3H); 2.12–2.32 (stack, 4H); 2.32–2.43 (stack, 2H). ¹³C-NMR ((D₆)acetone): *rac-3b*: 19.10 (t); 21.75 (q); 26.50 (q); 27.67 (t); 38.82 (t); 76.58 (s); 82.15 (s); 86.20 (s); 167.43 (s); *meso-3b*: 19.00 (t); 21.40 (q); 25.93 (q); 27.56 (t); 38.53 (t); 76.59 (s); 82.04 (s); 86.33 (s); 167.41 (s). MS (*meso/rac*): no *M*⁺, 234(5), 220(3), 219(7), 203(58), 192(29), 187(30), 173(11), 169(11), 159(22), 145(16), 143(18), 131(26), 119(13), 117(13), 105(19), 91(24), 77(13), 43(100).

3,6-Dimethylocta-1,7-diyne-3,6-diyl Diacetate (5b). To a soln. of 3,6-dimethylocta-1,7-diyne-3,6-diol (0.5 g, 3.01 mmol; **5a**) [20] in pyridine (25 ml) was slowly added Ac₂O (0.97 g, 9.06 mmol) and DMAP (0.15 g, 1.23 mmol) at 0° and stirred for 1.5 h. The mixture was warmed to r.t. and stirring continued for 24 h. Workup and chromatography with Et₂O gave 0.45 g (60%) of **5b**. White solid. M.p. 52°. *R_f* 0.68 (Et₂O). GC: *t_R* 12.45, 12.54 (52:48). IR: 3310s, 3000m, 2940m, 2120w, 1740vs, 1445m, 1370s, 1240vs, 1175m, 1060m, 1015m, 940m. ¹H-NMR (CDCl₃): 1.59 (s, 6H); 1.92 (s, 6H); 1.92–2.11 (stack, 4H); 2.49 (s, 2H). ¹³C-NMR (CDCl₃): major isomer: 21.80 (q); 26.42 (q); 36.05 (t); 73.66 (s); 74.10 (d); 83.32 (s); 169.20 (s); minor isomer: 21.80 (q); 26.32 (q); 35.99 (t); 73.64 (s); 74.06 (s); 83.29 (s); 169.20 (s). GC-MS: 208 ([*M* – 43]⁺, 0.5), 166(24), 165 ([*M* – 43 – 43]⁺, 27), 149(10), 138(15), 137(10), 133(17), 117(11), 116(11), 105(13), 91(18), 80(19), 79(33), 69(9), 53(13), 43(100). Anal. calc. for C₁₄H₁₈O₄ (250.29): C 67.18, H 7.25; found: C 67.46, H 7.43.

Cyclododeca-2,8-diyne-1-yl Methanesulfonate (11b). As described in [20], cyclododeca-2,8-diyne-1-ol (0.1 g, 0.57 mmol; **11a**) [20] was dissolved in CH₂Cl₂ (7 ml) at –5°. After the addition of Et₃N (0.234 g 2.31 mmol) and MsCl (0.216 g, 1.88 mmol), the mixture was stirred for 4 h at 0°. Workup with 2*N* HCl and extraction with Et₂O gave 0.132 g (91%) of **11b** as a white powder which could be used without further purification. *R_f* 0.73 (Et₂O). IR: 2930vs, 2860s, 2235m, 1740m, 1680m, 1315m, 1165vs, 1090m, 1010m, 965s, 900vs. ¹H-NMR ((D₆)acetone): 1.59–1.99 (stack, 6H); 2.00–2.40 (stack, 8H); 3.19 (s, 3H); 5.24 (*dm*, 1H). ¹³C-NMR ((D₆)acetone): 19.10 (t); 19.30 (t); 19.39 (t); 24.59 (t); 27.33 (t); 28.40 (t); 35.42 (t); 39.13 (q); 73.13 (d); 78.08 (s); 81.48 (s); 82.32 (s); 90.95 (s). MS: 255 ([*M* + 1]⁺, 0.5), 254 (*M*⁺, 4), 221(5), 220(23), 206(15), 205(77), 189(5), 175(20), 158(24), 157(32), 147(22), 143(33), 131(40), 130(52), 129(77), 128(50), 117(55), 115(66), 105(41), 103(33), 91(87), 81(27), 79(100), 78(36), 77(60), 67(39), 65(42), 55(40), 51(36), 41(61), 39(66).

2. Acyclic and Cyclic Diallenes 4, 5, and 8 and Allen-yne 12. 1,3,6,8-Tetramethylcyclododeca-1,2,6,7-tetraene (4). To a slurry of CuI (0.244 g, 1.28 mmol) in Et₂O (2.6 ml) was slowly added MeLi (1.60 ml, 1.6*M*, 2.56 mmol) at –15°. After 20 min, *meso*-**3b** (0.098 mg, 0.324 mmol) in Et₂O (0.8 ml) was added and stirred at –10° for 30 min. The mixture was warmed to r.t. and stirred for another 24 h. Workup and chromatography with pentane gave *meso*-**4** (63 mg, 90%) as a colorless liquid. Under the same conditions, the transformation of *rac*-**3b** gave *rac*-**4** in 91% yield.

meso-**4**: *R_f* 0.61 (pentane). GC (*cf. Footnote 2*): *t_R* 26.49; column *A* (isothermal at 120°): *t_R* 47.70. IR: 2960vs, 2940vs, 2900vs, 2860vs, 1965w, 1470s, 1455s, 1370s. ¹H-NMR (CDCl₃): 1.63 (s, 6H); 1.67 (s, 6H); 1.68–1.80 (stack, 4H); 1.93–2.06 (stack, 4H); 2.14–2.36 (stack, 4H). ¹³C-NMR (CDCl₃): 19.48 (q); 19.70 (q); 25.61 (t); 31.82 (t); 32.25 (t); 96.35 (s); 97.64 (s); 199.40 (s). MS: 217 ([*M* + 1]⁺, 17), 216 (*M*⁺, 100), 201(27), 187(13), 173(20), 161(6), 160(8), 159(49), 146(9), 145(40), 133(17), 131(15), 119(33), 105(18), 91(16), 77(12), 67(5), 41(15). HR-MS: 216.1876 (C₁₆H₂₄⁺; calc. 216.1878).

rac-**4**: *R_f* 0.61 (pentane). GC (*cf. Footnote 2*): *t_R* 25.82; column *A* (60–200° (2°/min)): *t_R* 47.91, 48.50 (1:1). IR: 2960vs, 2940vs, 2900vs, 2860vs, 1965w, 1470s, 1455s, 1370s. ¹H-NMR (CDCl₃): 1.628 (s, 6H); 1.634 (s, 6H); 1.73–2.03 (stack, 8H); 2.22 (d, 2H); 2.25 (d, 2H). ¹³C-NMR (CDCl₃): 18.28 (q); 20.97 (q); 26.37 (t); 32.03 (t); 33.29 (t); 96.67 (s); 97.18 (s); 199.65 (s). MS: 217 ([*M* + 1]⁺, 18), 216 (*M*⁺, 100), 201(24), 187(10), 173(17), 161(5), 160(7), 159(43), 146(7), 145(35), 133(15), 131(13), 119(30), 105(16), 91(14), 77(10), 67(5), 55(8), 41(15). HR-MS: 216.1877 (C₁₆H₂₄⁺; calc. 216.1878).

4,7-Dimethyldeca-2,3,7,8-tetraene (6). As described for **4**, with **5b** (1.44 g, 5.77 mmol). Workup and chromatography with pentane gave 0.85 g (91%) of **6**. Colorless liquid. *R_f* 0.72 (pentane). GC: **6** was not stable under GC conditions [23] [24]. IR: 2950vs, 2920vs, 2900vs, 2870vs, 1970m, 1470s, 1445s, 1370s, 1270m, 1145m, 995m. ¹H-NMR (CDCl₃): 1.64 (*dd*, 6H); 1.69 (d, 6H); 2.04 (s, 4H); 5.01 (stack, 2H). ¹³C-NMR (CDCl₃): major isomer: 14.83 (q); 19.24 (q); 32.02 (t); 84.93 (d); 98.44 (s); 201.93 (s); minor isomer: 14.87 (q); 19.28 (q); 32.08 (t); 84.96 (d); 98.50 (s); 201.93 (s). MS: 161 ([*M* – 1]⁺, 1), 151(6), 148(8), 147 ([*M* – 15]⁺, 93), 137(12), 133(62), 119(17), 105(29), 91(24), 85(17), 71(34), 57(76), 43(100).

1,8-Di(tert-butyl)cyclododeca-1,2,6,7-tetraene (8). To **7b** [20] (84 mg, 0.24 mmol) and CuI (93 mg, 0.45 mmol) in THF (5 ml) was added at –30° a freshly prepared *t*-BuMgCl soln. in Et₂O (1 ml, 1.0 mmol; obtained from Mg (292 mg, 12 mmol) and *t*-BuCl (926 mg, 10 mmol) in Et₂O (10 ml)). The mixture was stirred for 30 min, then warmed to r.t. and stirred for 1 h. Workup and chromatography with pentane gave 47.2 mg (72%) of **8** as a colorless liquid which formed white crystals at –18°. M.p. 48°. *R_f* 0.55 (pentane). GC: *t_R* 37.69, 37.58 (1:3); column *A* (isothermal at 110°): *t_R* 59.93 (74%; *meso* + 1/2 *rac*), 63.24 (26%; 1/2 *rac*): IR: 2975vs, 2960vs, 2920vs, 2880vs, 2850vs, 1955m, 1720w, 1465vs, 1450vs, 1360s, 1340m, 1290m, 1240s, 1205s, 1090m. ¹H-NMR (CDCl₃): 1.03 (s, 18H); 1.78–2.34 (stack, 12H); 4.94–5.16 (stack, 2H). ¹³C-NMR (CDCl₃): major isomer: 26.58 (t); 27.07 (t); 29.33 (q); 29.73 (t); 33.29 (s); 92.65 (d); 113.10 (s); 199.84 (s); minor isomer: 26.58 (t); 27.17 (t); 29.46 (q); 29.73 (t); 33.39 (s); 92.91 (d); 113.30 (s); 199.87 (s). MS: 273 ([*M* + 1]⁺, 5), 272 (*M*⁺, 22), 257(5), 216(22), 215(46), 201(20), 193(12), 173(24), 160(20), 159(67), 131(29), 105(17), 95(17), 91(19), 85(36), 57(100), 43(33). HR-MS: 272.2504 (C₂₀H₃₂⁺; calc. 272.2504).

1-(tert-Butyl)cyclododeca-1,2-dien-7-yne (**12**). As described for **7b**, with **11b** (0.13 g, 0.512 mmol): 0.06 g (54%) of **12**. Colorless liquid. R_f 0.39 (pentane). GC: t_R 29.86. IR: 2940m, 2900m, 2820s, 2320m, 1950m, 1450s, 1435vs, 1390m, 1360vs, 1330m, 1110vs, 1020s, 980m, 900s. $^1\text{H-NMR}$ (CDCl_3): 1.02 (s, 9H); 1.48–1.98 (stack, 8H); 2.00–2.43 (stack, 6H); 5.10 (stack, 1H). $^{13}\text{C-NMR}$ (CDCl_3): 17.89 (t); 19.19 (t); 25.15 (t); 25.18 (t); 26.44 (t); 27.92 (t); 28.54 (t); 29.29 (q); 33.53 (s); 81.22 (s); 83.08 (s); 94.56 (d); 112.74 (s); 199.41 (s). MS: 216 (M^+ , 9), 201(45), 173(26), 159(100), 145(25), 131(63), 117(49), 105(27), 91(49), 79(25), 77(23), 67(20), 57(32), 41(48). HR-MS: 216.1875 ($\text{C}_{16}\text{H}_{24}^+$; calc. 216.1878).

REFERENCES

- [1] W. R. Moore, R. C. Bertelson, *J. Org. Chem.* **1962**, *27*, 4182.
- [2] P. Crabbé, E. Barreiro, J.-M. Dollat, J.-L. Luche, *J. Chem. Soc., Chem. Commun.* **1976**, 183.
- [3] P. Rona, P. Crabbé, *J. Am. Chem. Soc.* **1968**, *90*, 4733.
- [4] J.-L. Luche, E. Barreiro, J.-M. Dollat, P. Crabbé, *Tetrahedron Lett.* **1975**, 4615.
- [5] P. Crabbé, H. Carpio, *J. Chem. Soc., Chem. Commun.* **1972**, 904.
- [6] P. Vermeer, J. Meijer, L. Brandsmaa, *Recl. Trav. Chim. Pays-Bas* **1975**, *94*, 112.
- [7] P. Vermeer, H. Westmijze, H. Kleijn, L. A. van Dijck, *Recl. Trav. Chim. Pays-Bas* **1978**, *97*, 56.
- [8] J.-L. Moreau, M. Gaudemar, *J. Organomet. Chem.* **1976**, *108*, 159.
- [9] K. A. Parker, J. J. Petratis, *Tetrahedron Lett.* **1977**, 4561.
- [10] I. Marek, P. Mangeney, A. Alexakis, J. F. Normant, *Tetrahedron Lett.* **1986**, *27*, 5499.
- [11] A. Alexakis, A. Commercon, J. Villiéras, J. F. Normant, *Tetrahedron Lett.* **1976**, 2313.
- [12] A. Alexakis, P. Mangeney, J. F. Normant, *Tetrahedron Lett.* **1985**, *6*, 4197.
- [13] D. J. Pasto, R. H. Shults, J. A. McGrath, A. Waterhouse, *J. Org. Chem.* **1978**, *43*, 1382.
- [14] A. Claesson, L.-I. Olsson, *J. Am. Chem. Soc.* **1979**, *101*, 7302.
- [15] L. A. van Dijck, B. J. Lankwerden, J. G. C. M. Vermeer, A. J. M. Weber, *Recl. Trav. Chim. Pays-Bas* **1971**, *90*, 801.
- [16] L. Skattebol, *Acta Chem. Scand.* **1963**, *17*, 1683.
- [17] R. P. Johnson, *Mol. Struct. Energ.* **1986**, *3*, 85.
- [18] P. J. Garratt, K. C. Nicolaou, F. Sondheimer, *J. Am. Chem. Soc.* **1973**, *95*, 4582.
- [19] H. Irngartinger, H.-U. Jäger, *Tetrahedron Lett.* **1976**, 3595.
- [20] C. Boss, R. Keese, *Helv. Chim. Acta* **1996**, *79*, 2164.
- [21] T. Tabuchi, J. Inanaga, M. Yamaguchi, *Tetrahedron Lett.* **1986**, *27*, 5237.
- [22] T. Tabuchi, J. Inanaga, M. Yamaguchi, *Chem. Lett.* **1987**, 2275.
- [23] D. J. Pasto, *Tetrahedron* **1984**, *40*, 2805.
- [24] S. Braverman, Y. Duar, *Tetrahedron Lett.* **1978**, 1493.
- [25] O. Eisenstein, G. Procter, J. D. Dunitz, *Helv. Chim. Acta* **1978**, *61*, 2538.